Bolt Biotherapeutics Inc. (BOLT)
Bolt Biotherapeutics Statistics
Share Statistics
Bolt Biotherapeutics has 38.34M shares outstanding. The number of shares has increased by 0.56% in one year.
| Shares Outstanding | 38.34M |
| Shares Change (YoY) | 0.56% |
| Shares Change (QoQ) | 0.17% |
| Owned by Institutions (%) | 48.81% |
| Shares Floating | 25.24M |
| Failed to Deliver (FTD) Shares | 10.35K |
| FTD / Avg. Volume | 7.85% |
Short Selling Information
The latest short interest is 65.99K, so 0.17% of the outstanding shares have been sold short.
| Short Interest | 65.99K |
| Short % of Shares Out | 0.17% |
| Short % of Float | 0.26% |
| Short Ratio (days to cover) | 0.54 |
Valuation Ratios
The PE ratio is -0.32 and the forward PE ratio is -0.56. Bolt Biotherapeutics's PEG ratio is 0.03.
| PE Ratio | -0.32 |
| Forward PE | -0.56 |
| PS Ratio | 2.66 |
| Forward PS | 0.6 |
| PB Ratio | 0.36 |
| P/FCF Ratio | -0.33 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Bolt Biotherapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.2, with a Debt / Equity ratio of 0.44.
| Current Ratio | 3.2 |
| Quick Ratio | 3.2 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | -0.38 |
| Debt / FCF | -0.41 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $147.88K |
| Profits Per Employee | $-1.21M |
| Employee Count | 52 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -72.86% in the last 52 weeks. The beta is 0.94, so Bolt Biotherapeutics's price volatility has been higher than the market average.
| Beta | 0.94 |
| 52-Week Price Change | -72.86% |
| 50-Day Moving Average | 0.46 |
| 200-Day Moving Average | 0.6 |
| Relative Strength Index (RSI) | 33.89 |
| Average Volume (20 Days) | 131.83K |
Income Statement
In the last 12 months, Bolt Biotherapeutics had revenue of 7.69M and earned -63.12M in profits. Earnings per share was -1.65.
| Revenue | 7.69M |
| Gross Profit | 7.69M |
| Operating Income | -73.05M |
| Net Income | -63.12M |
| EBITDA | -66.45M |
| EBIT | -68.24M |
| Earnings Per Share (EPS) | -1.65 |
Balance Sheet
The company has 7.21M in cash and 25.21M in debt, giving a net cash position of -18M.
| Cash & Cash Equivalents | 7.21M |
| Total Debt | 25.21M |
| Net Cash | -18M |
| Retained Earnings | -427.4M |
| Total Assets | 99.63M |
| Working Capital | 34.96M |
Cash Flow
In the last 12 months, operating cash flow was -61.29M and capital expenditures -41K, giving a free cash flow of -61.33M.
| Operating Cash Flow | -61.29M |
| Capital Expenditures | -41K |
| Free Cash Flow | -61.33M |
| FCF Per Share | -1.61 |
Margins
Gross margin is 100%, with operating and profit margins of -949.91% and -820.78%.
| Gross Margin | 100% |
| Operating Margin | -949.91% |
| Pretax Margin | -820.78% |
| Profit Margin | -820.78% |
| EBITDA Margin | -864.17% |
| EBIT Margin | -949.91% |
| FCF Margin | -797.53% |
Dividends & Yields
BOLT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BOLT is $1.12, which is 194.7% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.12 |
| Price Target Difference | 194.7% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -7.55 |
| Piotroski F-Score | 2 |